Arbutus Biopharma Corp (Nasdaq:ABUS)
Health Care/Life Sciences • Pharmaceuticals
CIK 1447028
Company
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Address
701 Veterans Circle
Warminster, Pennsylvania 18974
701 Veterans Circle
Warminster, Pennsylvania 18974
Employees
None
None
Stock Info
Close
$2.7000
$2.7000
Day Range
2.6800 - 2.7550
2.6800 - 2.7550
52 Week Range
1.6900 - 3.1450
1.6900 - 3.1450
Average volume
956.56K
956.56K
Short Interest
3.69M (02/15/24)
3.69M (02/15/24)
% of Float Shorted
2.75%
2.75%
Market Cap
$491.81M
$491.81M
Revenue
$18.14M
$18.14M
Net Income
N/A
N/A
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
President, Chief Executive Officer, COO & Director Michael J McElhaugh MBA |
Director Melissa V Rewolinski PhD |
Chairman Frank M Torti MD, MBA |
Independent Director James R Meyers |
Independent Director Richard C Henriques Jr., MBA |
Independent Director Daniel D Burgess MBA |
Independent Director Keith S Manchester MD |
SEC filings
Date | Form | Event |
---|---|---|
16 Aug, 2024 | 4 | |
8 Aug, 2024 | 10-Q | |
8 Aug, 2024 | S-8 | |
5 Aug, 2024 | 8-K | |
1 Aug, 2024 | 8-K | |
10 Jun, 2024 | SC 13G | |
6 Jun, 2024 | 8-K | |
5 Jun, 2024 | 8-K | |
28 May, 2024 | 8-K | |
24 May, 2024 | 4 | |
24 May, 2024 | 4 | |
24 May, 2024 | 4 | |
24 May, 2024 | 4 | |
24 May, 2024 | 4 | |
24 May, 2024 | 4 | |
22 May, 2024 | 8-K | |
17 May, 2024 | SC 13D/A | |
9 May, 2024 | SC 13D | |
2 May, 2024 | 10-Q | |
2 May, 2024 | 8-K | |
2 May, 2024 | 8-K | |
10 Apr, 2024 | DEF 14A | |
10 Apr, 2024 | DEFA14A | |
4 Apr, 2024 | 8-K | |
5 Mar, 2024 | 10-K | |
29 Feb, 2024 | 8-K | |
14 Feb, 2024 | SC 13G/A | |
14 Feb, 2024 | SC 13G/A | |
12 Feb, 2024 | SC 13G/A | |
5 Feb, 2024 | 4 | |
5 Feb, 2024 | 4 | |
5 Feb, 2024 | 4 | |
5 Feb, 2024 | 4 | |
5 Feb, 2024 | 4 | |
8 Jan, 2024 | 8-K | |
4 Jan, 2024 | 8-K | CEO Change |
21 Nov, 2023 | SC 13G | |
9 Nov, 2023 | 8-K | |
7 Nov, 2023 | 8-K | CEO Change |
7 Nov, 2023 | 8-K | |
7 Nov, 2023 | 10-Q | |
11 Oct, 2023 | 8-K | |
11 Sep, 2023 | 8-K | |
11 Sep, 2023 | SC 13G | |
3 Aug, 2023 | 8-K | |
3 Aug, 2023 | 10-Q | |
3 Aug, 2023 | S-8 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 4 | |
12 Jul, 2023 | 4 | |
12 Jul, 2023 | 3 | |
12 Jul, 2023 | 3 | |
12 Jul, 2023 | 8-K | |
12 Jul, 2023 | 4 | |
10 Jul, 2023 | 8-K | |
21 Jun, 2023 | 8-K | |
21 Jun, 2023 | 8-K | |
7 Jun, 2023 | 8-K | |
30 May, 2023 | 8-K | |
26 May, 2023 | 4 | |
26 May, 2023 | 4 | |
26 May, 2023 | 4 | |
26 May, 2023 | 4 | |
26 May, 2023 | 4 | |
4 May, 2023 | 8-K | |
4 May, 2023 | 10-Q | |
27 Apr, 2023 | 8-K | |
25 Apr, 2023 | 8-K | |
18 Apr, 2023 | 8-K | |
12 Apr, 2023 | DEFA14A | |
12 Apr, 2023 | DEF 14A | |
4 Apr, 2023 | 8-K | |
16 Mar, 2023 | 8-K | |
14 Mar, 2023 | 8-K | |
2 Mar, 2023 | 8-K | |
2 Mar, 2023 | 10-K | |
3 Feb, 2023 | 4 | |
3 Feb, 2023 | 4 | |
3 Feb, 2023 | 4 | |
3 Feb, 2023 | 4 | |
3 Feb, 2023 | SC 13G | |
3 Feb, 2023 | 4 | |
27 Jan, 2023 | 8-K | |
5 Jan, 2023 | 8-K | |
13 Dec, 2022 | 8-K | |
9 Nov, 2022 | 10-Q | |
9 Nov, 2022 | 8-K | |
4 Nov, 2022 | 8-K | |
1 Nov, 2022 | 8-K | |
31 Oct, 2022 | 8-K | |
24 Oct, 2022 | 8-K | |
30 Sep, 2022 | 8-K | |
30 Aug, 2022 | 8-K | |
4 Aug, 2022 | 8-K | |
4 Aug, 2022 | 10-Q | |
4 Aug, 2022 | S-8 | |
20 Jul, 2022 | 8-K | |
27 Jun, 2022 | 8-K | |
8 Jun, 2022 | 8-K | |
6 Jun, 2022 | 8-K | |
31 May, 2022 | 8-K | |
26 May, 2022 | 4 | |
26 May, 2022 | 4 | |
26 May, 2022 | 4 | |
26 May, 2022 | 4 | |
26 May, 2022 | 8-K | |
26 May, 2022 | 4 | |
26 May, 2022 | 4 | |
24 May, 2022 | 8-K | |
5 May, 2022 | 8-K | |
11 Apr, 2022 | DEFA14A | |
11 Apr, 2022 | DEF 14A | |
3 Mar, 2022 | 8-K | |
3 Mar, 2022 | 8-K | |
3 Mar, 2022 | 424B5 | |
3 Mar, 2022 | 10-K | |
28 Feb, 2022 | 8-K | |
14 Feb, 2022 | SC 13G/A | |
24 Jan, 2022 | 8-K | |
20 Jan, 2022 | 4 | |
20 Jan, 2022 | 4 | |
20 Jan, 2022 | 4 | |
20 Jan, 2022 | 4 | |
20 Jan, 2022 | 4 | |
20 Jan, 2022 | 4 | |
30 Dec, 2021 | D | |
14 Dec, 2021 | 8-K | |
13 Dec, 2021 | 8-K | |
10 Dec, 2021 | 8-K | |
7 Dec, 2021 | 8-K | |
3 Dec, 2021 | 4 | |
1 Dec, 2021 | 8-K | |
18 Nov, 2021 | EFFECT | |
16 Nov, 2021 | CORRESP | |
16 Nov, 2021 | UPLOAD | |
12 Nov, 2021 | 8-K | |
12 Nov, 2021 | 8-K | |
12 Nov, 2021 | 4 | |
12 Nov, 2021 | 3 | |
4 Nov, 2021 | 10-Q | |
4 Nov, 2021 | 8-K | |
4 Nov, 2021 | S-3 | |
20 Oct, 2021 | 4 | |
20 Oct, 2021 | SC 13D/A | |
8 Oct, 2021 | 424B5 | |
8 Oct, 2021 | 8-K | |
5 Aug, 2021 | S-8 | |
5 Aug, 2021 | 8-K | |
5 Aug, 2021 | 10-Q | |
14 Jul, 2021 | 8-K | |
7 Jul, 2021 | 8-K | |
6 Jul, 2021 | 8-K | |
29 Jun, 2021 | 8-K | |
28 Jun, 2021 | 8-K | |
7 Jun, 2021 | 4 | |
7 Jun, 2021 | 4 | |
7 Jun, 2021 | 4 | |
7 Jun, 2021 | 4 | |
7 Jun, 2021 | 4 | |
7 Jun, 2021 | 4 | |
1 Jun, 2021 | 8-K | |
5 May, 2021 | 8-K | |
5 May, 2021 | 10-Q | |
8 Apr, 2021 | DEF 14A | |
8 Apr, 2021 | DEFA14A | |
1 Apr, 2021 | 8-K | |
16 Mar, 2021 | 8-K | |
4 Mar, 2021 | 8-K | |
4 Mar, 2021 | 424B5 | |
4 Mar, 2021 | 8-K | |
4 Mar, 2021 | 10-K | |
26 Feb, 2021 | 8-K | |
17 Feb, 2021 | 4 | |
17 Feb, 2021 | 4 | |
17 Feb, 2021 | 4 | |
17 Feb, 2021 | 4 | |
17 Feb, 2021 | 4 | |
17 Feb, 2021 | 4 | |
16 Feb, 2021 | SC 13G/A | |
12 Feb, 2021 | SC 13G/A | |
10 Feb, 2021 | SC 13G/A | |
10 Feb, 2021 | 4 | |
1 Feb, 2021 | 8-K | |
25 Jan, 2021 | 8-K |
Last update:2024-03-08 12:06:38.223076
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.